<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711982</url>
  </required_header>
  <id_info>
    <org_study_id>2016TON Study</org_study_id>
    <nct_id>NCT02711982</nct_id>
  </id_info>
  <brief_title>Surgery for Traumatic Optic Neuropathy</brief_title>
  <official_title>Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of Traumatic Optic Neuropathy (TON) include a primary and secondary
      mechanism of injury. At present, no studies validate a particular approach to the management
      of TON. There are three management lines for these patients that include 1)observation
      only;2)medical treatment with high or megadoses of methylprednisolone; and 3)surgical
      intervention. Studies have shown that forces applied to the frontal bone and malar eminences
      are transferred and concentrated in the area near the optic canal. The tight adherence of the
      optic nerve's dural sheath to the periosteum within the optic canal is also thought to
      contribute to this segment of the nerve being extremely susceptible to the deformative
      stresses of the skull bones. In this study, investigators aim to make a randomized controlled
      trial to certify the efficiency of optic nerve canal decompression for TON patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      surgical intervention's efficiency and outcome for TON patients will be clearly present after
      this randomized controlled trial study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude and Latency of Visual-Evoked Potential</measure>
    <time_frame>from trauma day to 60 days after trauma</time_frame>
    <description>Name of Scale: Visual-Evoked Potential Physiological Parameter: Amplitude and Latency Questionnaire: Trauma day and 1 day, 2 days, 3 days, 7 days, 14 days, 30 days and 60 days after trauma. Two more test for the day before surgery（Medical） and the day after surgery(Medical).
Measurement collection: Inpatient and outpatient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vision level of Visual Acuity</measure>
    <time_frame>from trauma day to 60 days after trauma</time_frame>
    <description>Name of Scale: Level Vision and Visual acuity chart from 0.1 to 1.5 Physiological Parameter: light perception, hand motion and Visual Acuity Chart from 0.1 to 1.5 Questionnaire: Trauma day and 1 day, 2 days, 3 days, 7 days, 14 days, 30 days and 60 days after trauma. Two more test for the day before surgery（Medical） and the day after surgery(Medical).
Measurement collection: Inpatient and outpatient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Traumatic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Optic nerve decompression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optic canal and optic nerve sheath decompression within 5 days from trauma occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a maximum daily dose of 1 g of methylprednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optic canal and optic nerve sheath decompression</intervention_name>
    <description>within 5 days from trauma</description>
    <arm_group_label>Optic nerve decompression</arm_group_label>
    <other_name>optic decompression</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>within 5 days from trauma</description>
    <arm_group_label>methylprednisolone</arm_group_label>
    <other_name>steroids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the history of Traumatic Brain Injury or Craniofacial Trauma

          -  Optic nerve compression（intraneural edema, nerve sheath hematoma or canal fracture
             with impingement)

          -  Amplitude and latency abnormal or Ratio of amplitude of abnormal to normal side.

        Exclusion Criteria:

          -  Glasgow Coma Scale，Score&lt;8

          -  Patients with good Visual Acuity and Visual Evoked Potential amplitude ratio more than
             50%

          -  Other Contraindications for surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lijun Hou, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lijun Hou, MD,PhD</last_name>
    <phone>86 21 81885671</phone>
    <email>houlijunsmmu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hai Jin, MD,PhD</last_name>
    <phone>86 21 81885688</phone>
    <email>kingsea300809@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery,ShangHai ChangZheng Hospital</name>
      <address>
        <city>ShangHai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai Jin, M.D.,PhD</last_name>
      <phone>86 21 81885671</phone>
      <email>kingsea300809@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Hou Lijun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

